Parsaclisib, also known as INCB050465, is a novel PI3Kδ inhibitor which synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. INCB050465 inhibits PI3Kδ (IC50 = 1 nM at 1 mM ATP) with approximately 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases. INCB050465 demonstrates potent activity with IC50 values ranging from 0.2 to 2 nM. In addition, INCB050465 blocks the proliferation of several DLBCL and MCL cell lines in vitro (EC50 < 10 nM) and can slow tumor growth in the Pfeiffer model of DLBCL in vivo.
For research use only. We do not sell to patients.
Name | Parsaclisib HCl |
---|---|
Iupac Chemical Name | (4R)-4-{3-[(1S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one hydrochloride |
Synonyms | INCB50465 HCl; INCB-50465; INCB 50465; INCB050465 HCl; INCB-050465; INCB 050465; INCB050465 free base; Parsaclisib hydrochloride; Parsaclisib HCl; |
Molecular Formula | C20H23Cl2FN6O2 |
Molecular Weight | 469.34 |
Smile | O=C1NC[C@@H](C2=C(F)C(Cl)=CC([C@@H](N3N=C(C)C4=C(N)N=CN=C43)C)=C2OCC)C1.[H]Cl |
InChiKey | TWHUONANZMKBKX-ACMTZBLWSA-N |
InChi | InChI=1S/C20H22ClFN6O2.ClH/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20;/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26);1H/t10-,11-;/m0./s1 |
CAS Number | 1995889-48-9 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
---|---|
Purity | 98% Min. |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |